Rockwell Medical (NASDAQ:RMTI – Free Report) had its price target cut by HC Wainwright from $9.00 to $7.00 in a research report report published on Monday,Benzinga reports. They currently have a buy rating on the stock.
A number of other research firms also recently issued reports on RMTI. Rodman & Renshaw assumed coverage on shares of Rockwell Medical in a research note on Thursday, November 14th. They issued a “buy” rating and a $5.00 price target on the stock. RODMAN&RENSHAW raised shares of Rockwell Medical to a “strong-buy” rating in a research note on Thursday, November 14th. Finally, StockNews.com downgraded shares of Rockwell Medical from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st.
View Our Latest Analysis on Rockwell Medical
Rockwell Medical Price Performance
Institutional Investors Weigh In On Rockwell Medical
Several large investors have recently added to or reduced their stakes in the business. Armistice Capital LLC increased its stake in Rockwell Medical by 22.5% during the 2nd quarter. Armistice Capital LLC now owns 3,221,640 shares of the company’s stock worth $5,670,000 after buying an additional 592,000 shares during the period. Vanguard Group Inc. increased its stake in Rockwell Medical by 4.0% during the 1st quarter. Vanguard Group Inc. now owns 1,118,277 shares of the company’s stock worth $1,856,000 after buying an additional 43,302 shares during the period. Jane Street Group LLC purchased a new stake in Rockwell Medical during the 3rd quarter worth approximately $534,000. Walleye Capital LLC purchased a new stake in Rockwell Medical during the 3rd quarter worth approximately $435,000. Finally, Renaissance Technologies LLC increased its stake in Rockwell Medical by 877.1% during the 2nd quarter. Renaissance Technologies LLC now owns 102,700 shares of the company’s stock worth $181,000 after buying an additional 92,189 shares during the period. 23.31% of the stock is owned by hedge funds and other institutional investors.
About Rockwell Medical
Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.
Read More
- Five stocks we like better than Rockwell Medical
- Stock Dividend Cuts Happen Are You Ready?
- Abacus Life’s CEO on Cracking the Code of Longevity Returns
- What is a SEC Filing?
- Elon Musk and Trump Push for Self-Driving Cars: 3 Stocks to Gain
- Stock Market Upgrades: What Are They?
- Discover the 3 Best Performing Stocks That Went Public in 2024
Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.